|
|
Article: Sirna Therapeutics licenses seminal RNA interference technology.(to the University of Massachusetts Medical School)
- Article from:
- BIOTECH Patent News
- Article date:
- September 1, 2003
CopyrightCOPYRIGHT 2003 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sirna Therapeutics, Inc. (Boulder, CO) has entered into a worldwide license agreement with the University of Massachusetts Medical School (Worcester, MA) for its undivided interest in the seminal intellectual property on RNA interference (RNAi) technology covering short interfering RNA (siRNA). This license significantly strengthens Sirna's broad RNAi intellectual property portfolio for the development of RNAi therapeutics.
The license covers the RNAi technology patent application filed by Tuschl, et al., International PCT Publication WO 01/75164, which was jointly developed and is owned by the University of Massachusetts Medical School, Max-Planck Institute, ...